Covered recipient · General Payments record
ROBYN R YOUNG
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$9,022.98
134 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,503.02 | 119 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,240.00 | 1 |
| Consulting Fee | $1,280.00 | 2 |
| Long term medical supply or device loan | $999.96 | 12 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ROBYN R YOUNG
NPI 1962452474 · CMS profile ID 361254
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
FORT WORTH, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1962452474?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ROBYN R YOUNG, NPI 1962452474, CMS profile ID 361254. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962452474?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). ROBYN R YOUNG, NPI 1962452474, CMS profile ID 361254. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962452474?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- ROBYN R YOUNG, NPI 1962452474, CMS profile ID 361254, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1962452474?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
134 matching records · $9,022.98 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–134 of 134.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Eisai Inc. | $23.45 | 04/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110777477 | CMS |
| Merck Sharp & Dohme LLC | $15.55 | 04/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141750459 | CMS |
| PUMA BIOTECHNOLOGY, INC. | $124.40 | 04/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113843818 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.66 | 03/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110545113 | CMS |
| PUMA BIOTECHNOLOGY, INC. | $12.85 | 03/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113851737 | CMS |
| Novartis Pharmaceuticals Corporation | $21.27 | 03/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087346738 | CMS |
| E.R. Squibb & Sons, L.L.C. | $13.17 | 03/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101234755 | CMS |
| Tactile Systems Technology Inc | $21.19 | 03/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1082372607 | CMS |
| Novartis Pharmaceuticals Corporation | $83.33 | 03/15/2024 | Long term medical supply or device loan | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087346760 | CMS |
| Novartis Pharmaceuticals Corporation | $20.41 | 03/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087346734 | CMS |
| Lilly USA, LLC | $13.60 | 03/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135337913 | CMS |
| SERVIER PHARMACEUTICALS LLC | $24.84 | 03/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147263135 | CMS |
| Eisai Inc. | $24.09 | 03/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110777475 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $23.86 | 03/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137701450 | CMS |
| AstraZeneca Pharmaceuticals LP | $30.97 | 02/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110547732 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.29 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110538447 | CMS |
| BeiGene USA, Inc. | $26.46 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120865020 | CMS |
| Gilead Sciences, Inc. | $111.33 | 02/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133802886 | CMS |
| Karyopharm Therapeutics Inc. | $18.38 | 02/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145536231 | CMS |
| Novartis Pharmaceuticals Corporation | $83.33 | 02/16/2024 | Long term medical supply or device loan | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087346758 | CMS |
| Karyopharm Therapeutics Inc. | $18.88 | 02/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145536227 | CMS |
| Eisai Inc. | $24.80 | 02/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110777479 | CMS |
| Incyte Corporation | $21.28 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141287660 | CMS |
| PharmaEssentia USA Corporation | $32.88 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137303128 | CMS |
| Adaptive Biotechnologies Corporation | $22.99 | 02/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150263555 | CMS |
| Novartis Pharmaceuticals Corporation | $20.32 | 01/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087346730 | CMS |
| Daiichi Sankyo Inc. | $24.82 | 01/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089501050 | CMS |
| AstraZeneca Pharmaceuticals LP | $125.00 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110535068 | CMS |
| Novartis Pharmaceuticals Corporation | $24.96 | 01/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087346732 | CMS |
| Novartis Pharmaceuticals Corporation | $11.13 | 01/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087346728 | CMS |
| Novartis Pharmaceuticals Corporation | $83.33 | 01/18/2024 | Long term medical supply or device loan | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087346756 | CMS |
| Stemline Therapeutics Inc. | $21.48 | 01/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1142963582 | CMS |
| Daiichi Sankyo Inc. | $24.53 | 01/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089501048 | CMS |
| AstraZeneca Pharmaceuticals LP | $30.99 | 01/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110545461 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $416,279.45 | 19 |
| PY2024 | Principal investigator | $311,020.69 | 33 |
| PY2023 | Recipient | $2,028.73 | 1 |
| PY2023 | Principal investigator | $452,965.16 | 32 |
| PY2022 | Principal investigator | $1,187,832.99 | 58 |
| PY2021 | Principal investigator | $845,269.59 | 44 |
| PY2020 | Principal investigator | $1,197,077.07 | 59 |
| PY2019 | Recipient | $1,529.00 | 1 |
| PY2019 | Principal investigator | $435,146.21 | 53 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
19 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $140,807.02 | 12/31/2025 | Non-covered Recipient Entity The Center for Cancer and Blood Disorders | An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Participants with HR,HER2-Unresectable Locally Advanced or Metastatic Breast Cancer | No dispute reported | 06/30/2026 | 1232923136 |
| Principal investigator 1 | PFIZER INC. | $3,525.00 | 11/17/2025 | Non-covered Recipient Entity THE CENTER FOR CANCER AND | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 | No dispute reported | 06/30/2026 | 1228728901 |
| Principal investigator 1 | PFIZER INC. | $3,525.00 | 11/10/2025 | Non-covered Recipient Entity THE CENTER FOR CANCER AND | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 | No dispute reported | 06/30/2026 | 1228737489 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,500.00 | 11/05/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK LLC | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | No dispute reported | 06/30/2026 | 1185542664 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 09/02/2025 | Non-covered Recipient Entity THE CENTER FOR CANCER AND | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 | No dispute reported | 06/30/2026 | 1228760175 |
| Principal investigator 1 | PFIZER INC. | $350.00 | 08/25/2025 | Non-covered Recipient Entity THE CENTER FOR CANCER AND | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 | No dispute reported | 06/30/2026 | 1228767836 |
| Principal investigator 1 | Genentech, Inc. | $535.00 | 08/20/2025 | Non-covered Recipient Entity CENTER FOR CANCER + BLOOD DISORDERS ONCOLOGY HEMATOLOGY CONSULTANTS PA | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211584745 |
| Principal investigator 1 | PFIZER INC. | $312.32 | 08/11/2025 | Non-covered Recipient Entity THE CENTER FOR CANCER AND | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 | No dispute reported | 06/30/2026 | 1228767899 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $56,353.39 | 07/29/2025 | Non-covered Recipient Entity THE CENTER FOR CANCER AND BLOOD DISORDERS | DESTINY-Breast07 will investigate the safety tolerability and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer | No dispute reported | 06/30/2026 | 1185542658 |
| Principal investigator 1 | Eli Lilly and Company | $20,036.00 | 06/10/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CONSULTANTS P A | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187888856 |
| Principal investigator 1 | Genentech, Inc. | $2,535.94 | 06/09/2025 | Non-covered Recipient Entity CENTER FOR CANCER + BLOOD DISORDERS ONCOLOGY HEMATOLOGY CONSULTANTS PA | Chemo trastuzumab vs chemo trastuzumab pertuzumab | No dispute reported | 06/30/2026 | 1211584730 |
| Principal investigator 1 | PFIZER INC. | $624.64 | 04/14/2025 | Non-covered Recipient Entity THE CENTER FOR CANCER AND | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 | No dispute reported | 06/30/2026 | 1228779955 |
| Principal investigator 1 | Genentech, Inc. | $5,371.00 | 04/08/2025 | Non-covered Recipient Entity CENTER FOR CANCER + BLOOD DISORDERS ONCOLOGY HEMATOLOGY CONSULTANTS PA | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | No dispute reported | 06/30/2026 | 1211584741 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,728.13 | 02/28/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK LLC | A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) | No dispute reported | 06/30/2026 | 1185542662 |
| Principal investigator 1 | Genentech, Inc. | $25,930.00 | 02/20/2025 | Non-covered Recipient Entity CENTER FOR CANCER + BLOOD DISORDERS ONCOLOGY HEMATOLOGY CONSULTANTS PA | Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC | No dispute reported | 06/30/2026 | 1211584737 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $17,665.68 | 02/14/2025 | Non-covered Recipient Entity THE CENTER FOR CANCER AND BLOOD DISORDERS | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1190303559 |
| Principal investigator 1 | Eli Lilly and Company | $1,512.10 | 02/10/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CONSULTANTS P A | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187888472 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $51,904.13 | 01/15/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK LLC | A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) | No dispute reported | 06/30/2026 | 1185542660 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $71,564.10 | 01/03/2025 | Non-covered Recipient Entity THE CENTER FOR CANCER AND BLOOD DISORDERS | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy | No dispute reported | 06/30/2026 | 1185542666 |